News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Hisamitsu Pharmaceutical , Nippon Shinyaku Co., Ltd. Conclude Joint Development Agreement For HFT-290 Cancer Pain Palliative Care Agent


10/19/2005 5:13:14 PM

Tokyo (JCNN) - Hisamitsu Pharmaceutical and Nippon Shinyaku (TSE: 4516) announced on April 7 that they have entered into a joint development agreement for HFT-290, a drug candidate for the treatment of cancer pain. The two companies will conduct Phase III clinicalt trials, and co-promote the new product in Japan.

Read at JCN Newswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES